StockData
Adaptive Biotechnologies Corp logo

Adaptive Biotechnologies Corp (ADPT) stock

ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/30
$28.49+0.62 (+2.22%)

Close on Nov 17, 2026Market cap $4.55BP/E –Yield –

Adaptive Biotechnologies operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Adaptive Biotechnologies's operating cash flow for the twelve months ending Jun 30, 2026 was -$21.01M. For fiscal 2025 it was -$45.99M. The highest annual figure on record is $205.40M in fiscal 2019.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$45.99M–
FY2024Dec 31, 2024-$95.21M–
FY2023Dec 31, 2023-$156.32M–
FY2022Dec 31, 2022-$183.95M–
FY2021Dec 31, 2021-$192.73M–
FY2020Dec 31, 2020-$149.68M-172.9%
FY2019Dec 31, 2019$205.40M–
FY2018Dec 31, 2018-$32.26M–
FY2017Dec 31, 2017-$34.86M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$6.40M–
Q1 FY2026Mar 31, 2026-$9.54M–
Q4 FY2025Dec 31, 2025$2.06M–
Q3 FY2025Sep 30, 2025-$7.13M–
Q2 FY2025Jun 30, 2025-$12.43M–
Q1 FY2025Mar 31, 2025-$28.48M–
Q4 FY2024Dec 31, 2024-$12.49M–
Q3 FY2024Sep 30, 2024-$27.07M–
Q2 FY2024Jun 30, 2024-$17.30M–
Q1 FY2024Mar 31, 2024-$38.35M–
Q4 FY2023Dec 31, 2023-$26.93M–
Q3 FY2023Sep 30, 2023-$46.68M–
Q2 FY2023Jun 30, 2023-$23.56M–
Q1 FY2023Mar 31, 2023-$59.15M–
Q4 FY2022Dec 31, 2022-$30.02M–
Q3 FY2022Sep 30, 2022-$42.41M–
Q2 FY2022Jun 30, 2022-$47.07M–
Q1 FY2022Mar 31, 2022-$64.45M–
Q4 FY2021Dec 31, 2021-$53.83M–
Q3 FY2021Sep 30, 2021-$43.44M–
Q2 FY2021Jun 30, 2021-$37.21M–
Q1 FY2021Mar 31, 2021-$58.25M–
Q4 FY2020Dec 31, 2020-$39.84M–
Q3 FY2020Sep 30, 2020-$47.16M–
Q2 FY2020Jun 30, 2020-$31.08M–
Q1 FY2020Mar 31, 2020-$31.61M-111.4%
Q4 FY2019Dec 31, 2019-$26.79M–
Q3 FY2019Sep 30, 2019-$30.14M–
Q2 FY2019Jun 30, 2019-$15.97M–
Q1 FY2019Mar 31, 2019$278.30M–
Q4 FY2018Dec 31, 2018-$5.41M–
Q3 FY2018Sep 30, 2018-$11.69M–

More Adaptive Biotechnologies figures

See a number that looks wrong?